Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

CPIX Price Correlated With Financials For Cumberland Pharmaceuticals

Free historical financial statements for Cumberland Pharmaceuticals Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with CPIX stock chart to see long term trends.

CPIX Stock Compared to Quarterly

CPIX Income Statement

Revenue, Net:11175045
Revenue Per Share:0.7568
Cost of Goods & Services Sold:2211885
Selling, General & Admin Expense:4614429
Research & Development Expense:1745136
Total Operating Expenses:12467044
Operating Income:-1395533
Income Taxes:6900
Net Income:-1402433
Earnings Per Share, Basic:-0.09
Shares Outstanding, Basic Avg:14766492

CPIX Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1653746
Change in Accounts Receiveable:7758089
Net Cash from Operations:-150498
Net Cash from Operations Per Share:-0.0102
Repurchases/Buybacks Common Stock:580130
Net Cash from Financing Activities:3918365
Property, Plant & Equipment Purchases:26986
Net Cash from Investing Activities:-13541898
Net Change in Cash & Equivalents:-9774031

CPIX Balance Sheet

Cash and Cash Equivalents:17266785
Accounts Receivable, Net:14635435
Inventories:9878680
Total Current Assets:45341927
Property, Plant & Equipment, Net:409121
Total Assets:96697106
Accounts Payable:11447505
Total Short-Term Liabilities:24557398
Total Liabilities:55903703

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Krogulski Kenneth   Director
1,069 sh at $3
$2,791
Buy
Galante Joseph C   Director
641 sh at $3
$1,673
Buy
Jones James   Director
318 sh at $3
$830
Buy
Young Caroline   Director
214 sh at $3
$559
Buy
COMPANY PROFILE
Organization Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets are hospital acute care, gastroenterology, rheumatology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.

Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.

In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace. In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (“Gloria”). As a result, Gloria received shares in CET and joined the CET ownership group.

In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited (WinHealth) whereby WinHealth made a $1.0 million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million investment in CET. Cumberland purchased additional CET shares through contribution of $0.3 million in cash and a conversion of $0.7 million in intercompany loans payable. Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $0.8 million that was funded during 2020.

The Company's ownership in CET is now 85%. While the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were $95,212, $79,496 and $8,752 for the years ended December 31, 2021, 2020 and 2019, respectively.

Effective January 1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC"). CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.

Data imported from Cumberland Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.